Ipamorelin: Famous for What It Does Not Do, and for a Trial Nobody Quotes

In plain English

Ghrelin is the hormone the stomach releases when it is empty. Besides making people hungry, it tells the pituitary gland to release growth hormone.

Ipamorelin is a synthetic five-amino-acid peptide that switches on the ghrelin receptor. It was built from an older compound by cutting two amino acids out of the middle, and the result turned out to be unusually clean: it triggers growth hormone without meaningfully raising the stress hormone cortisol or the milk hormone prolactin, which older compounds in the same family did. That selectivity is its whole reputation.

What it does not have is a successful human trial. The only completed randomised controlled study — in 114 adults recovering from bowel surgery — missed what it set out to measure ^[15]. It has never been approved as a drug anywhere, and it is banned in sport at all times.

It is also the compound whose own research record states, in plain terms, that its famous pairing has never been tested.

What it is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Alpha-aminoisobutyric acid sits at position 1; D-2-naphthylalanine and D-phenylalanine give it resistance to protease breakdown. It was derived from the earlier growth-hormone-releasing peptide GHRP-1 by removing the central alanine-tryptophan pair, and it also circulates under its development code NNC 26-0161.

Pharmacologically it is a selective agonist of the ghrelin receptor, formally the growth hormone secretagogue receptor 1a. Its signature property is a negative one. Unlike the earlier growth-hormone-releasing peptides GHRP-6 and GHRP-2, it does not meaningfully raise ACTH, cortisol or prolactin even at exposures far above those needed to release growth hormone. That is a genuine relative advantage over less selective compounds in the same class, and it is not a claim that it has no off-target effects at all.

Its standing: never approved as a drug for any indication anywhere. It was investigated for postoperative ileus and not approved. In 2024 the FDA removed ipamorelin acetate from category 2 of the interim section 503A bulk-substances list following the nominator's withdrawal, and reviewed ipamorelin acetate and free base at the October 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is sold only as a research chemical, and it is prohibited in sport at all times under WADA category S2, detectable in urine by accredited laboratories.

How it works

Ipamorelin activates the ghrelin receptor on pituitary somatotrophs, which triggers a pulse of growth-hormone release. The receptor is also expressed elsewhere — on enteric and vagal neurons involved in gastric motility, on pancreatic islet cells, and in the hypothalamic circuitry that governs appetite — which is why a compound marketed for the pituitary effect carries consequences well beyond it.

The mechanistic point that matters for this site is the route rather than the result. Growth hormone can be provoked two ways: through the GHRH receptor, which is where CJC-1295 acts, or through the ghrelin receptor, which is where ipamorelin acts. These are separate receptors with separate signalling, converging on the same pituitary output. Ipamorelin's own research record describes this explicitly as a mechanism distinct from and complementary to GHRH — and names that distinction as the basis for combining it with GHRH analogues.

That sentence is the clearest statement of a combination rationale anywhere in the four corpora behind this site. It is also, as the next section shows, a statement about mechanism and not about outcome.

What the research actually shows

The human efficacy record is one randomised trial, and it missed. In the only published phase 2 randomised controlled trial of ipamorelin, 114 adults undergoing open or laparoscopic bowel resection received 0.03 mg/kg intravenously twice daily for up to seven days. The primary endpoint — median time to first tolerated meal — was 25.3 hours with ipamorelin against 32.6 hours with placebo, which did not reach statistical significance at p=0.15. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of the placebo arm, so the study found no ipamorelin-specific safety signal in that short perioperative window ^[15]. The defining human study of this compound demonstrated tolerability and failed to demonstrate efficacy.

Human pharmacokinetics are well characterised and short. Population PK/PD modelling in healthy male volunteers — eight per dose level, given five 15-minute intravenous infusions ranging from 4.21 to 140.45 nmol/kg — found dose-proportional kinetics, a terminal half-life of about two hours, clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg. The growth-hormone response peaked at about 0.67 hours, roughly forty minutes after dosing, as a single discrete pulse ^[16].

The most recent in-vivo work is not about growth hormone at all. A 2024 ferret study found that intraperitoneal ipamorelin at 1-3 mg/kg inhibited cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase, 48 to 72 hours after chemotherapy, but had no anti-emetic effect in either the acute or the delayed phase — in contrast to intracerebroventricular anamorelin, which reduced acute emesis by 60% ^[13]. A peripheral effect on weight, no effect on nausea.

A rodent study shows a skeletal effect without a systemic marker. Subcutaneous ipamorelin at 18, 90 and 450 micrograms per day, divided into three daily portions for 15 days, raised the longitudinal bone growth rate of adult female Sprague-Dawley rats from 42 micrometres per day on vehicle to 44, 50 and 52 micrometres per day respectively — with no change in total IGF-1, IGF-binding proteins or bone turnover markers ^[17]. The effect appears to be driven by the growth-hormone pulse and local activity rather than by a measurable systemic IGF-1 shift.

And a class-level safety study that is not about ipamorelin, but frames it. An integrated preclinical safety-pharmacology study of GSK894281 — a structurally distinct agonist at the same receptor — found dose-dependent myocardial degeneration and necrosis in rats after 28 days of oral dosing, visible on histopathology and electron microscopy and accompanied by elevated serum heart-type fatty-acid-binding protein at the highest doses, while serum cardiac troponin was not elevated ^[14]. Ipamorelin itself was not the compound tested, and no equivalent long-duration cardiovascular study of ipamorelin exists in any species. That absence is the point.

What users report, and what the cautions say

What follows is anecdotal, not clinical evidence: community reports from peptide forums, clinic write-ups and consumer guides, with dose and source unknown and nothing measured under controlled conditions.

Deeper, more restorative sleep is the most consistently cited benefit and is frequently reported, often appearing within one to two weeks. Vivid dreams in the early weeks are frequently reported and generally described as settling down afterwards. Faster physical recovery and reduced post-training soreness are frequently reported, sometimes with a described improvement in how joints feel over several weeks. A gradual shift toward a leaner appearance is occasionally reported, typically from around weeks five to twelve, and is heavily confounded by whatever else the person is doing.

On the adverse side, facial flushing and a warm head-rush roughly five to fifteen minutes after injection is frequently reported and often likened to a niacin flush. Tingling or numbness in the hands and feet, mild water retention and puffiness, and injection-site redness or itching are each occasionally reported. Increased hunger in the hours after injection is occasionally reported, which is unsurprising given that the compound acts on the ghrelin receptor, and is generally described as milder than with GHRP-6. Early fatigue, dizziness or a 'spacey' feeling shortly after injecting is occasionally reported. Some report that perceived effects, particularly on sleep, fade after three to four months of uninterrupted use.

The documented cautions:

• Unknown long-term human safety, and unverified material. The controlled human dataset is one phase 2 trial over a seven-day perioperative window ^[15] plus an acute single-dose pharmacokinetic study ^[16]. There has been no phase 3 trial and there is no long-term human safety database. The dominant route in off-label research use is subcutaneous self-administration, which has no published safety or pharmacokinetic characterisation in humans at all. Research-grade material from unregulated suppliers carries no pharmaceutical quality assurance, so purity, peptide identity and sterility are unverified. These are documented gaps, not theoretical ones.
• Active or recent malignancy. Growth hormone drives hepatic IGF-1 production, and IGF-1 is a well-characterised mitogen. Chronically raising growth-hormone pulse amplitude raises a theoretical concern about proliferative activity in pre-existing or occult tumours ^[17]. No ipamorelin-specific carcinogenicity or tumour-promotion study exists in humans; the caution is mechanistic and class-level.
• Diabetes, impaired glucose tolerance or insulin resistance. Growth hormone is counter-regulatory and reduces peripheral insulin sensitivity. Ipamorelin additionally has a growth-hormone-independent insulinotropic action on pancreatic islet cells demonstrated in ex vivo rat tissue. The net glycaemic effect of those two opposing influences is unpredictable in anyone whose glucose handling is already disturbed, and no human glycaemic data exist for it at research-use exposures.
• Cardiovascular disease, heart failure or significant oedema. Growth-hormone excess is associated with sodium and water retention and cardiomegaly, and the class-level 28-day rodent finding described above makes chronic systemic agonism at this receptor a concern where the heart is already vulnerable ^[14].
• Appetite and adiposity. Agonists at this receptor activate hypothalamic appetite centres and induce feeding; ipamorelin has also shown growth-hormone-independent stimulation of adiposity and leptin elevation in mice. The orexigenic and adipogenic signal is class-level and is not fully neutralised by ipamorelin's selectivity for growth hormone.
• The selectivity itself is a genuine relative advantage. Not raising ACTH, cortisol or prolactin removes a concern that applies to less selective compounds in the same family. It is a comparative point, not a clean bill of health.

Why it ends up coupled to something else

Ipamorelin is the compound that makes the combination question unavoidable, because its own literature raises it and then answers it against interest.

The rationale is stated in the mechanism itself: growth-hormone release by a route distinct from and complementary to GHRH, which is named as the basis for combining it with GHRH analogues such as CJC-1295. Two receptors, one output. Add the duration mismatch — a discrete pulse peaking about forty minutes after dosing ^[16] against a background that persists for days ^[11] — and the design reads as deliberate rather than arbitrary.

Then comes the sentence this desk kept returning to. Ipamorelin's own record lists, among its open controversies, a combination-evidence gap: the popular pairing with CJC-1295 is supported by separate single-agent pharmacology, not by trials of the combination for any outcome. Not thin evidence. No evidence, for any endpoint.

What that means in practice is worth spelling out. Ipamorelin's best single-agent human evidence is a trial that missed its primary endpoint ^[15]. CJC-1295's is single-dose pharmacology in healthy volunteers ^[11][12]. A combination cannot be better evidenced than its constituents, and here the weaker constituent sets a low ceiling. Nothing about pairing the two lifts either one's evidence — and pairing them does compound the shared concerns, since both raise growth hormone and therefore IGF-1 exposure, and both come with fluid-retention and glucose cautions of their own.

The pairing is a hypothesis. It has been marketed for years as a conclusion.